A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Brief description of study
The purpose of the study is to evaluate the activity of a novel triplet combination of rituximab and hyaluronidase human, polatuzumab vedotin, and venetoclax for relapsed Mantle Cell Lymphoma (MCL) patients. We want to know how patients respond to treatment with the regimen of rituximab and hyaluronidase human + polatuzumab vedotin + venetoclax (RSC+Pola+Ven) in relapsed/ refractory MCL. During the study, we also want to find out the best response in patients who continue on to maintenance therapy and evaluate the improvement in the depth of response.
Clinical Study Identifier: s18-01339
ClinicalTrials.gov Identifier: NCT04659044
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
